Splunk Inc. (NASDAQ:SPLK)
Splunk Inc. (NASDAQ:SPLK) represented a move of 4.59 percent or $-2.06 per share and closed its previous day trading session at $99.84. 4.3 Million Shares were traded in the last trading session with an Average Volume of 2.34 Million Shares. The stock currently has a Market Capitalization of 15.25 Billion.
Splunk Inc. provides a software platform, which collects and indexes data and enables users to search, correlate, analyze, monitor and report on this data, all in real time. Its software is designed to help users in various roles, including IT and business professionals. Splunk Inc. is based in San Francisco, California.
The stock traded between $ 65.73 and $130.00 over 1-Year time period showing its price to sales ratio of 10.53. Splunk Inc. (NASDAQ:SPLK) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-11.14 and 200-Day Simple Moving Average of $-5.44. Its Price to Free Cash Flow is 52.83 and Price to Book of 12.62.
Analyst’s recommended the stock as 1.9 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Splunk Inc. (NASDAQ:SPLK) reported its Actual EPS of $0.08/share. The analysts offering Earnings Estimates for the company were believing that Splunk Inc. could bring EPS of $0.05/share. The difference between Actual EPS and Estimated EPS was 0.03 Percent. Thus showing an Earnings Surprise of 60 Percent.
Novavax, Inc. (NASDAQ:NVAX)
In the last trading session, Novavax, Inc. (NASDAQ:NVAX) added its value by 3.53% closing at the price of $1.76. The stock currently has market capitalization of 692.23 Million, with average volume of 5.85 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Novavax, Inc. (NASDAQ:NVAX) is showing beta of 2.44. This particular value of beta suggests that Novavax, Inc. (NASDAQ:NVAX) has historically moved 244% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Novavax, Inc. (NASDAQ:NVAX) is at $-0.57.
The stock currently has RSI of 45.97. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.
Novavax, Inc. (NASDAQ:NVAX) topped its 52-week high price of $2.75 on 03/01/18 and 52-Week Low Price of $1.05 on 12/20/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 8.20% and monthly volatility of 7.73% respectively.